1 J. S. Ayres, Sci. Adv 10.1126 / sciadv.abc1518 (2020)
About Arch Biopartners
Arch Biopartners Inc.es a clinically stage company aimed at developing cutting-edge technologies that have the potential to have a significant medical or advertising impact. Arch is preparing a line of new candidate drugs that inhibit inflammation in the lungs, liver and kidneys through the dipeptidase-1 pathway (DPEP-1) for medical indications.
The Company has 60,782,302 common shares outstanding.